Headquartered in 7-11 Boulevard Haussmann, Paris·Fiscal year ends December·NASDAQ: ABVX·abivax.com
About Abivax SA
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis (UC) and in Phase 2b trials for Crohn's disease (CD). Abivax is listed on both Euronext Paris and Nasdaq. The company is currently pre-revenue, investing heavily in late-stage clinical development and pre-commercial infrastructure as it prepares for a planned NDA submission for obefazimod in UC by end of 2026. Abivax operates across France and the United States and maintains a debt-free balance sheet following the completion of its royalty certificate buy-back program. Updated
Pre-Market Stock Futures: Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up…
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the…
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
What is the ABVX stock price target?
The Wall Street consensus 12-month price target for ABVX is $163.58.